German biotech CureVac has canceled manufacturing contracts with two prospective partners for its Covid-19 vaccine CVnCoV while retaining others. The company said on Sept...

First to receive US approval under an Emergency Use Authorization (EUA) in late 2020, the BioNTech/Pfizer Covid-19 vaccine on Aug. 23 became the first to be fully...

As the delta variant of the coronavirus tears through the US, pushing both new and breakthrough infections higher, the US Centers for Disease Control (CDC) has now come...

As it continues to grapple with documentation issues, US biotech Novavax has again altered its timeline for seeking Emergency Use Authorization (EUA) from the US Food and...

Pfizer and BioNTech applied to the US Food and Drug Administration (FDA) in May for full authorization of their Covid-19 vaccine Comirnaty, and in the interest of...

As part of a new supply chain partnership, South Africa’s Biovac will produce Pfizer and BioNTech’s Comirnaty-branded Covid-19 vaccine at its Capetown site from the end...

Definitive results from CureVac’s 40,000-subject international Phase 2b/3 trial with its mRNA-based Covid-19 vaccine candidate, CVnCoV, have confirmed an earlier finding...

South Korea-based CDMO SK Bioscience, with cash in hand from an initial public offering, has announced plans to pour 150 billion won ($132 million) into vaccine...